drug
LETROZOLE
Marketedupdated 5mo agoby Yiling Pharmaceutical Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Breast Cancer
all catalysts(9)
approval · 9
Jun 3, 2011
approval
LETROZOLE — FDA approval
LETROZOLE
→
May 15, 2012
approval
LETROZOLE — FDA approval
LETROZOLE
→
Jul 19, 2014
approval
LETROZOLE — FDA approval
LETROZOLE
→
Feb 13, 2015
approval
LETROZOLE — FDA approval
LETROZOLE
→
Feb 13, 2015
approval
LETROZOLE — FDA approval
LETROZOLE
→
Apr 2, 2021
approval
LETROZOLE — FDA approval
LETROZOLE
→
Apr 2, 2021
approval
LETROZOLE — FDA approval
LETROZOLE
→
Oct 1, 2025
approval
LETROZOLE — FDA approval
LETROZOLE
→
Oct 1, 2025
approval
LETROZOLE — FDA approval
LETROZOLE
→
Trials studying LETROZOLE
- phase2Study of AVZO-021 in Patients With Advanced Solid Tumors
- phase3A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- phase3Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- phase4Roll-over Study to Allow Continued Access to Ribociclib
- phase2ALPINE: Maintenance Letrozole/Abemaciclib
- phase3BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- phase1A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 17, 2027
353 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (11)
- Apr 14, 2036formulationUS 10799506
- Apr 14, 2036formulationUS 12064434
- Apr 14, 2036formulationUS 12419894
- Aug 7, 2034method-of-use (U-3998)US 12544380
- Nov 9, 2031compositionUS 9193732
- Nov 9, 2031method-of-use (U-3264)US 9868739
- Mar 13, 2031compositionUS 84153554.5y
- May 25, 2030compositionUS 86859803.7y
- Dec 9, 2029method-of-use (U-3264)US 89626303.2y
- Aug 20, 2029method-of-use (U-3264)US 94161362.9y
- Jun 17, 2028compositionUS 83242251.7y
FDA exclusivities (1)
- Sep 17, 2027I-951Indication (3y)353d
News(3)
- Opinion: Telehealth abortion with mifepristone continues, with backup plans still in placeRestricting telehealth prescribing of mifepristone wouldn't spell the end of telehealth medication abortion, writes OB-GYN Christine Henneberg.stat · 4mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 4mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 4mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that